To highlight the advantages of mRNA therapy, we compared the in vivo half-life and therapeutic effects of sPD-L1 mRNA-LNPs with a commercially available PD-L1-Fc recombinant protein in a murine model of ARDS. This evidence concerns the gene CD274 and acute respiratory distress syndrome.